Brainstorm Cell Therapeutics Approves Stock Plan Amendments

An announcement from Brainstorm Cell Therapeutics ( (BCLI) ) is now available.

On June 25, 2025, Brainstorm Cell Therapeutics Inc. held its Annual Meeting of Stockholders, where amendments to the 2014 Stock Incentive Plan and 2014 Global Share Option Plan were approved. These amendments increase the pool of shares available for issuance by 2,000,000 shares, impacting the company’s stock incentives and potentially enhancing its ability to attract and retain talent. Additionally, the stockholders elected seven board members, ratified the appointment of a new accounting firm, and approved compliance with Nasdaq Listing Rule 5635(d), reflecting significant governance and operational decisions.

The most recent analyst rating on (BCLI) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Brainstorm Cell Therapeutics stock, see the BCLI Stock Forecast page.

Spark’s Take on BCLI Stock

According to Spark, TipRanks’ AI Analyst, BCLI is a Underperform.

Brainstorm Cell Therapeutics’ stock score is significantly impacted by its financial performance challenges, including ongoing losses and negative cash flows. While there are strategic advancements and partnerships aimed at derisking the regulatory pathway, the company’s valuation and technical indicators reflect a bearish outlook. Investors should be cautious due to financial constraints and skepticism regarding the efficacy of its lead treatment, NurOwn.

To see Spark’s full report on BCLI stock, click here.

More about Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc. operates in the biotechnology industry, focusing on developing innovative cellular therapies for neurodegenerative diseases.

Average Trading Volume: 1,349,232

Technical Sentiment Signal: Sell

Current Market Cap: $9.76M

For a thorough assessment of BCLI stock, go to TipRanks’ Stock Analysis page.